AI Medical Technology Authorizations Surge to Record High in 2026

Artificial intelligence medical technology is no longer waiting outside the purchasing committee room. In 2025, the FDA authorized 295 AI/ML-enabled medical devices, the highest annual total reported to date, with a median review time of 142 days and 221 unique manufacturers represented in that year’s authorizations.[1] By mid-2026, the cumulative U.S. authorization count has moved past 1,400, large enough that health systems can no longer treat the category as a small experimental annex to medical device procurement.[1]

The useful question is not whether AI has arrived in medical devices. It has. The harder question is what kind of arrival this is: which specialties account for most authorizations, what functions the devices actually perform, what regulatory pathways brought them to market, and how much confidence a clearance should carry when a procurement team is writing service-level terms, validation requirements, monitoring obligations, and exit clauses.

The answer is uneven. The authorization curve is steep, but the market it describes is still concentrated, mostly image-centered, overwhelmingly dependent on 510(k), and only beginning to use the regulatory tools meant to manage controlled algorithm updates after authorization.

The Record Year Is Real, But It Is Not Evenly Distributed

The 2025 authorization count deserves to be taken seriously. A single-year total of 295 authorizations is not a rounding error or a marketing mood; it is a documented acceleration in FDA-cleared AI/ML medical devices.[1] MedTech Dive’s interactive tracker, updated through March 2026, also shows continued acceleration rather than a one-year anomaly.[4]

But the distribution matters as much as the total. Innolitics reported that 71.5% of all AI/ML device clearances were in radiology, compared with 8.8% in cardiovascular medicine and 4.7% in neurology.[1] That is not a diversified clinical market with a light radiology tilt. It is a radiology-dominant market with several smaller specialty clusters around it.

For radiology leaders, that concentration has a practical upside: there is a deeper bench of authorized tools, more precedent in image-based workflows, and more experience integrating AI outputs into reading environments. For enterprise procurement, the same concentration is a warning against using the overall authorization count as shorthand for maturity across the hospital. A strong FDA authorization record in image analysis does not automatically translate into comparable maturity in inpatient deterioration, medication management, behavioral health, revenue-cycle-adjacent clinical tools, or generative documentation support.

The point is not that radiology AI is overrepresented by accident. Imaging produces structured digital inputs, repeatable interpretation tasks, and measurable outputs that fit more naturally into device evaluation than many other clinical settings. That makes radiology a plausible early center of gravity. It also means the AI medical device market is more mature in some kinds of perception and measurement tasks than in broader clinical reasoning.

Most Authorized Devices Are Still Image-Centered

The specialty distribution becomes clearer when paired with a taxonomy published in npj Digital Medicine. Across 1,016 FDA authorizations through September 2024, Singh and colleagues found that 84.4% were image-based, with quantification or feature localization identified as the dominant AI function.[2] That finding helps explain why radiology is not merely the largest clinical bucket; it is the organizing logic behind much of the authorized market.

Many of these tools are not attempting to replace broad clinical judgment. They may measure, flag, segment, localize, prioritize, or generate data from inputs a clinician already reviews. The npj analysis reported 106 devices using AI for data generation, which is a different proposition from autonomous diagnosis or open-ended clinical reasoning.[2] For a buyer, those distinctions should change the evaluation file. A triage or notification tool raises different workflow and liability questions than a measurement tool; an image segmentation function requires different validation than a patient-facing recommendation system.

The same taxonomy also reported zero LLM-based devices among authorizations through September 2024.[2] That statement should be read with its time boundary intact. It does not mean FDA will never authorize devices that use large language models, and it does not cover every submission under review after that cutoff. It does mean that, at least through that taxonomy window, the authorized AI/ML device market was not the same thing as the generative AI boom visible in health system pilots and vendor demonstrations.

This is where procurement language often gets sloppy. “FDA-authorized AI” can refer to a narrow imaging function with a defined intended use, not a general-purpose assistant. If a vendor presentation moves quickly from a cleared function to broader platform claims, the device committee should slow the conversation down to the authorized indication, input type, output, user, and workflow role.

SaMD Is Becoming the Default Form Factor

The 2025 data also show a structural shift in form: 62% of that year’s clearances were Software as a Medical Device, or SaMD.[1] This matters because software procurement behaves differently from capital equipment procurement. Versioning, cybersecurity review, interface dependencies, cloud terms, downtime procedures, model monitoring, and update governance all move closer to the center of the contract.

A SaMD-heavy market also changes who must be in the room. Radiology operations may judge whether an alert fits reading workflow. IT may judge integration burden. Clinical engineering may ask how the device is inventoried and monitored. Regulatory affairs may ask whether a planned update stays within the cleared device’s boundaries. Legal and compliance teams may care less about the phrase “AI” than about who bears responsibility when the model output is unavailable, delayed, overridden, or contradicted by the clinician.

The practical file for an AI SaMD purchase should therefore include more than the clearance letter. It should identify the FDA-authorized intended use, the deployment environment assumed by the vendor, the training and validation evidence the vendor is willing to disclose, the local monitoring plan, the update process, the data rights attached to ongoing performance improvement, and the escalation route when users report performance concerns.

510(k) Dominance Is the Central Regulatory Fact

The most important regulatory number is not the annual authorization count. It is the pathway distribution. The American Hospital Association told FDA that more than 96% of authorized AI devices had come through the 510(k) pathway, which is based on substantial equivalence and does not require de novo clinical studies.[3]

That should not be turned into a blanket accusation against cleared devices. The 510(k) pathway is a longstanding device mechanism, and substantial equivalence can be an appropriate route for many technologies. The procurement error is different: treating 510(k) clearance as if it independently proves improved outcomes in the purchasing hospital’s patient population, workflow, hardware environment, staffing model, and case mix.

A clearance answers a regulatory question. It does not, by itself, answer every operational question a health system has to answer before deployment. A committee still needs to know whether the evidence includes external validation, whether the study population resembles the local population, whether the comparator is clinically meaningful, whether the device changes turnaround time or merely adds another queue, whether false positives create downstream burden, and whether clinicians can understand when the model is likely to fail.

This distinction is particularly important for AI-enabled devices because performance can depend on data distributions, acquisition protocols, scanner settings, image quality, documentation conventions, and user behavior. A device that performs acceptably under one deployment pattern can still require careful implementation controls elsewhere. FDA authorization starts the evaluation; it should not end it.

PCCPs Are Promising, Not Yet Proven

Predetermined Change Control Plans are the policy mechanism to watch because they address one of the awkward features of AI-enabled software: the product may need controlled changes after authorization. In 2025, however, only 10.2% of AI/ML device clearances included PCCPs.[1] That is enough to show adoption has begun, but not enough to conclude that PCCPs have solved update governance, algorithm drift, or post-market safety monitoring.

For buyers, the question is not simply whether a vendor says the model improves over time. The question is whether the permitted changes are defined, how performance will be assessed before and after an update, what notice the health system receives, whether local validation is required, and who can pause or roll back deployment if the updated model behaves differently in practice.

A PCCP can make update expectations more explicit. It does not eliminate the need for contract language and governance inside the health system. If anything, it gives regulatory affairs, IT, clinical leadership, and procurement a more concrete object to review: the planned modification types, the methods for controlling those modifications, and the boundaries beyond which a new regulatory submission may be needed.

The Market Forecast Is Large, But the Authorization Data Are More Useful

Commercial pressure will keep rising. MarketsandMarkets projects the global AI in healthcare market to grow from $36.67 billion in 2026 to $194.79 billion in 2031.[5] That is a forecast, not evidence that any particular device improves care, lowers cost, or fits a hospital’s workflow. It is most useful as a signal that procurement teams should expect more vendor volume, more bundled AI claims, and more pressure to evaluate software faster.

The authorization data are more actionable than the market forecast because they show what has actually cleared FDA review. They show a market that is large and accelerating, but also lopsided toward radiology, shaped by image-based functions, dominated by 510(k), increasingly delivered as SaMD, and only beginning to use PCCPs.

That is the procurement-facing conclusion for Q3 2026. “FDA-authorized AI” is a meaningful starting point, especially in a category with more than 1,400 cumulative authorizations.[1] It is not a complete purchasing standard. The device still has to be read through its specialty, intended use, input type, output, regulatory pathway, evidence base, update plan, and local monitoring burden.

References

1. 2025 Year in Review, Innolitics, Dec 2025.
2. FDA-authorized artificial intelligence and machine learning-enabled medical devices: A taxonomy and analysis, npj Digital Medicine, July 2025.
3. AHA Letter to FDA, American Hospital Association, Dec 2025.
4. FDA AI medical device tracker, MedTech Dive, May 2026.
5. AI in Healthcare Market, MarketsandMarkets.